Aurinia Pharmaceuticals Inc.

NasdaqGM:AUPH Stock Report

Market Cap: US$2.0b

Aurinia Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:AUPH Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
03 Mar 26BuyUS$12,688,806Tang Capital Management, LLCCompany900,000US$14.38
03 Mar 26BuyUS$7,720,561Tang Capital Management, LLCCompany544,948US$14.38
03 Mar 26BuyUS$12,665,798Tang Capital Management, LLCCompany898,400US$14.33
27 Feb 26BuyUS$23,008Tang Capital Management, LLCCompany1,600US$14.38
12 Aug 25SellUS$5,435,971ILJIN SNT Co., LtdCompany498,538US$11.49
05 Aug 25BuyUS$13,590,000Tang Capital Management, LLCCompany1,300,000US$11.68
01 Aug 25BuyUS$5,691,488Tang Capital Management, LLCCompany562,400US$10.12
01 Aug 25SellUS$210,000Gregory KeenanIndividual20,000US$10.50
23 Jul 25SellUS$944,680Eun Huh SeoungIndividual108,000US$8.91

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of AUPH?
Owner TypeNumber of SharesOwnership Percentage
Public Companies1,123,6080.874%
Individual Insiders1,471,2051.14%
General Public45,541,66235.4%
Institutions80,465,19662.6%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 46.44% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
9.51%
Tang Capital Management, LLC
12,229,500US$186.1m7.94%8.57%
6.1%
BlackRock, Inc.
7,845,521US$119.4m-1.04%no data
4.21%
ILJIN SNT Co., Ltd
5,411,533US$82.4m0%no data
3.09%
New Enterprise Associates, Inc.
3,969,834US$60.4m0%3.83%
2.67%
Two Sigma Investments, LP
3,428,705US$52.2m74.7%0.04%
2.55%
Arrowstreet Capital, Limited Partnership
3,284,368US$50.0m-3.04%0.02%
1.97%
State Street Global Advisors, Inc.
2,527,099US$38.5m1%no data
1.67%
Morgan Stanley
2,141,955US$32.6m1.2%no data
1.46%
Marshall Wace LLP
1,874,597US$28.5m19%0.03%
1.29%
Renaissance Technologies LLC
1,663,835US$25.3m4.63%0.04%
1.22%
D. E. Shaw & Co., L.P.
1,572,983US$23.9m2.66%0.02%
1.19%
Geode Capital Management, LLC
1,536,009US$23.4m1.87%no data
0.98%
Vanguard Portfolio Management, LLC
1,256,361US$19.1m0%no data
0.87%
Lotte Chemical Corporation
1,123,608US$17.1m0%no data
0.85%
Jacobs Levy Equity Management Inc
1,097,189US$16.7m-3.69%0.06%
0.81%
LSV Asset Management
1,039,576US$15.8m58.3%0.03%
0.75%
Nomura Holdings, Inc.
968,910US$14.7m-16.2%0.04%
0.74%
Numeric Investors LLC
951,412US$14.5m12.1%0.04%
0.73%
AQR Capital Management, LLC
941,313US$14.3m96.8%0.01%
0.72%
Qube Research & Technologies Ltd
930,631US$14.2m6.44%0.02%
0.64%
Northern Trust Global Investments
824,105US$12.5m2.99%no data
0.62%
Jupiter Fund Management Plc
803,419US$12.2m-10.7%0.03%
0.61%
Goldman Sachs Asset Management, L.P.
787,988US$12.0m2.45%no data
0.59%
Janus Henderson Group plc
757,435US$11.5m9.67%no data
0.58%
BNP Paribas Financial Markets SNC
748,765US$11.4m19.7%0.01%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/26 10:39
End of Day Share Price 2026/05/26 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aurinia Pharmaceuticals Inc. is covered by 18 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David MartinBloom Burton & Co.
Dae Gon HaBTIG
Neil MaruokaCanaccord Genuity